SYDNEY, AAP – Demand for flu and COVID-19 vaccines helped CSL raise full-year profit by 10 per cent but the medicines provider is forecasting a leaner year ahead.
CSL on Wednesday said its flu vaccine business Seqirus had a revenue boom of 30 per cent which helped a net profit after tax of $US2.37 billion.
Greater numbers of people around the world used flu vaccines in response to the coronavirus threat.
CSL also manufactures the AstraZeneca coronavirus vaccine for Australians. However sales of this vaccine were not among the main contributors to its global revenue.
Chief executive Paul Perreault said the cost of collecting blood plasma to make its products would continue to be higher.
The earnings forecast for this financial year is between $US2.15 billion and $US2.25 billion.
Shareholders will receive a final dividend of $US1.18 per share. That is more than the $US1.07 per share paid this time last year.
Shares on the ASX were down 1.29 per cent to $294.11 at 1118 AEST.